SAT0436 Durability of apremilast response in patients with psoriatic arthritis: long-term (208-week) results from the palace 1 trial
Arthur Kavanaugh(Inflammation Research Foundation), J. Wollenhaupt(Schön Klinik Hamburg Eilbek), M. McIlraith(Bristol-Myers Squibb (Switzerland)), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Georg Schett(Karolinska University Hospital), JJ Gómez-Reino(Complejo Hospitalario Universitario de Santiago), Stephen Hall(Cabrini Hospital), Gladman Dd(Toronto Western Hospital), P. J. Mease(Providence College), Maria Paris(Amgen (United States)), Lichen Teng(Harbin Medical University), Éric Lespessailles(Université d'Orléans)
Cited by 0
Related Papers
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis Care & Research|2015|1.1k
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin
|Journal of Clinical Investigation|2012|708
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
|Annals of the Rheumatic Diseases|2008|540
EULAR definition of difficult-to-treat rheumatoid arthritis
|Annals of the Rheumatic Diseases|2020|538